-

Piper Sandler Advises Bain and Cinven on their acquisition of Lonza Specialty Ingredients

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler & Co. chemicals & materials investment banking group (The Valence Group) served as lead financial advisor to Bain Capital Private Equity and Cinven on their joint acquisition of Lonza Specialty Ingredients (LSI), a division of Lonza AG. The transaction, valued at CHF 4.2 billion (USD 4.7 billion), is expected to close in 2021, subject to customary closing conditions including regulatory clearances.

LSI is a world-leading provider of specialty chemicals for microbial control solutions, used to eliminate or control harmful and unwanted micro-organisms. LSI’s products are critical ingredients in disinfectants, preservatives, sanitizers, personal care products, as well as coatings and other industrial uses. Headquartered in Basel, Switzerland, LSI has approximately 2,800 employees, 11 R&D centers and 17 manufacturing sites across the world. The business serves circa 5,300 customers across a wide range of end-markets.

“Piper Sandler is extremely pleased to have played a significant supporting role in advising two long-term private equity clients in such a landmark transaction,” said Telly Zachariades, co-head of chemicals & materials investment banking at Piper Sandler (New York).

Anton Ticktin, managing director, Piper Sandler (London), further commented, “Our team has helped to deliver yet another multi-billion dollar, cross-border transaction, one of the largest LBOs in the chemical industry.” Ian George, managing director, Piper Sandler (London), added, “We look forward to helping Bain and Cinven write the next chapter of the LSI story.”

Peter Hall, head of European investment banking at Piper Sandler stated, “This transaction reflects the strong position we have in targeted sectors of the European investment banking market”.

ABOUT PIPER SANDLER

Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in Europe through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Sandler Hong Kong Limited, authorized and regulated by the Securities and Futures Commission. Private equity strategies and fixed income advisory services are offered through separately registered advisory affiliates.

Follow Piper Sandler: LinkedIn | Facebook | Twitter

©2021. Since 1895. Piper Sandler Companies. 800 Nicollet Mall, Minneapolis, Minnesota 55402-7036

Contacts

Pamela Steensland
Tel: 612 303-8185
pamela.steensland@psc.com

Piper Sandler & Co.

NYSE:PIPR

Release Summary
Piper Sandler Advises Bain and Cinven on their acquisition of Lonza Specialty Ingredients
$Cashtags

Contacts

Pamela Steensland
Tel: 612 303-8185
pamela.steensland@psc.com

More News From Piper Sandler & Co.

Piper Sandler Strengthens Fixed Income Platform with the Addition of Distressed Debt and Special Asset Group

NEW YORK--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the additions of John Mori and Eric Friel as managing directors to lead a new group that will focus on distressed debt and special assets. Mori will be based in Greenwich and Friel will be in New York, both reporting to Michael Piper, head of fixed income at Piper Sandler. The distressed debt and special asset group will source and trade specialized credit products, including distr...

Piper Sandler Companies Reports First Quarter 2026 Results; Increases Quarterly Dividend to $0.20 Per Share

MINNEAPOLIS--(BUSINESS WIRE)--The complete earnings release can be found on the firm's website at pipersandler.com/earnings...

Piper Sandler Strengthens Healthcare Investment Banking Team with the Addition of Patrick McCormack

MINNEAPOLIS & SAN FRANCISCO--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Patrick McCormack, M.D. as a managing director in the healthcare investment banking group. McCormack will be based in San Francisco and focused on advising biopharma companies on mergers and acquisitions and capital-raising transactions. “We are excited to welcome Patrick to the healthcare investment banking team. His deep expertise advising bioph...
Back to Newsroom